Microcarrier cell culture seed expansion patents: who holds the inoculum train, and where filing has cooled
Concentrated but not locked up. the top 5 assignees hold 23.6% of all 611 records in scope, and the top 10 hold 37.6% — a real lead, but well short of a lockout. Annual filings rose to a peak of 40 in 2021, then fell to 6 by 2024 — an 85% decline over that three-year window. Counts for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so the true trajectory for those years is not yet visible in this data.
- 1WILSON WOLF MANUFACTURING CORP46
- 2GENZYME CORP29
- 3DEPUY SYNTHES PROD INC25
- 4NOVO NORDISK HEALTH CARE AG25
- 5PRESIDENT & FELLOWS OF HARVARD COLLEGE19
See the full microcarrier cell culture seed expansion analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in microcarrier cell culture seed expansion?
Based on this 611-record dataset, one assignee leads with 46 families, well ahead of the fifth-ranked holder at 19 and the tenth-ranked holder at 16. Even so, the top 5 combined account for only 23.6% of all records in scope and the top 10 for 37.6%, so no single organisation or small group controls the field outright. A full assignee ranking of 100 companies is available for anyone doing detailed freedom-to-operate work, since most of the filing volume sits outside the top 10.
Is the microcarrier cell culture patent field still growing?
Filing volume peaked at 40 records in 2021 and had fallen to 6 by 2024, an 85% decline over that three-year span. That is the last year in this dataset that can be treated as complete, because publication typically lags filing by around 18 months, so 2025 and 2026 figures are still filling in. On the evidence available, the field has cooled substantially from its 2021 peak rather than continuing to expand.
What does US20190276846A1 actually cover?
This Ferring Ventures filing describes seeding an adherent-cell bioreactor with suspension-adapted, non-adherent producer cells instead of adherent cells, a method the applicant states raises the achievable seeding density limit and shortens the time between seeding and harvest. It is a process claim around how the bioreactor is inoculated, not a claim on the bioreactor hardware itself or on the cell line used. Anyone working on inoculation strategy for adherent-cell bioreactors should read the claim set directly rather than relying on the abstract, since the value of the invention is in the specific seeding method described.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Microcarrier Cell Culture Seed Expansion covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.